Antares Pharma, Inc. (NASDAQ:ATRS) – Stock analysts at Jefferies Group lifted their Q3 2017 earnings estimates for Antares Pharma in a research report issued on Tuesday. Jefferies Group analyst A. Petrone now forecasts that the specialty pharmaceutical company will post earnings of ($0.03) per share for the quarter, up from their prior estimate of ($0.04). Jefferies Group also issued estimates for Antares Pharma’s Q4 2017 earnings at ($0.02) EPS, FY2017 earnings at ($0.09) EPS and FY2018 earnings at ($0.07) EPS.
Antares Pharma (NASDAQ:ATRS) last issued its quarterly earnings results on Tuesday, August 8th. The specialty pharmaceutical company reported ($0.02) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.03) by $0.01. Antares Pharma had a negative return on equity of 41.37% and a negative net margin of 34.27%. The company had revenue of $13.42 million for the quarter, compared to analysts’ expectations of $12.99 million.
ATRS has been the topic of several other reports. Vetr upgraded Antares Pharma from a “hold” rating to a “buy” rating and set a $3.30 price target on the stock in a research report on Wednesday, July 5th. Chardan Capital began coverage on Antares Pharma in a research report on Friday, June 23rd. They set a “buy” rating and a $5.00 price target on the stock. HC Wainwright restated a “buy” rating and set a $5.00 price target on shares of Antares Pharma in a research report on Friday, June 23rd. Piper Jaffray Companies set a $4.00 price target on Antares Pharma and gave the stock a “buy” rating in a research report on Wednesday, July 26th. Finally, Raymond James Financial, Inc. began coverage on Antares Pharma in a research report on Thursday, April 20th. They set a “strong-buy” rating and a $4.30 price target on the stock. One research analyst has rated the stock with a hold rating, three have assigned a buy rating and two have given a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus price target of $3.83.
Antares Pharma (ATRS) opened at 2.87 on Friday. The company’s market cap is $448.89 million. Antares Pharma has a 52-week low of $1.01 and a 52-week high of $3.37. The firm has a 50-day moving average price of $3.15 and a 200-day moving average price of $2.76.
In related news, insider Fred M. Powell purchased 130,000 shares of Antares Pharma stock in a transaction that occurred on Friday, June 9th. The shares were acquired at an average cost of $2.79 per share, for a total transaction of $362,700.00. Following the transaction, the insider now directly owns 331,434 shares in the company, valued at $924,700.86. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 11.60% of the stock is owned by company insiders.
A number of institutional investors have recently bought and sold shares of ATRS. Alliancebernstein L.P. bought a new position in Antares Pharma during the second quarter valued at about $119,000. Legal & General Group Plc bought a new position in Antares Pharma during the second quarter valued at about $120,000. Credit Suisse AG bought a new position in Antares Pharma during the first quarter valued at about $146,000. National Planning Corp raised its position in Antares Pharma by 11.5% in the second quarter. National Planning Corp now owns 58,233 shares of the specialty pharmaceutical company’s stock valued at $186,000 after buying an additional 6,000 shares during the last quarter. Finally, KCG Holdings Inc. raised its position in Antares Pharma by 48.8% in the first quarter. KCG Holdings Inc. now owns 66,717 shares of the specialty pharmaceutical company’s stock valued at $189,000 after buying an additional 21,881 shares during the last quarter. Institutional investors and hedge funds own 31.70% of the company’s stock.
Antares Pharma Company Profile
Antares Pharma, Inc (Antares) is a specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies. The Company develops, manufactures and commercializes therapeutic products using its drug delivery systems. Its subcutaneous injection technology platforms include VIBEX disposable pressure-assisted auto injector system suitable for branded and generic injectable drugs in unit dose containers, reusable needle-free spring-action injector devices, and disposable multi-use pen injectors for use with cartridges.
Receive News & Ratings for Antares Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antares Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.